KRAS and RASopathy: In a series of 13336 colorectal cancers, p.V14 was identified as a KRAS mutation hotspot and p.V14 mutations have previously been associated with a range of RASopathies (53,54), supporting our finding that KRAS p.V14 mutations are rare but oncogenic.